Maastricht University

Performance and behavioral effects of illicit drugs

Citation for published version (APA):

Schmitt, J. A. J., Lamers, C. T. J., Kuypers, K. P. C., Ramaekers, J. G., & Riedel, W. J. (2006). Performance and behavioral effects of illicit drugs. In M. Burns (Ed.), *Medical legal aspects of drugs* (pp. 71-90). Lawyers & Judges.

Document status and date:
Published: 01/01/2006

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 07 Nov. 2026

ResearchGate

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/215606807

Performance and behavioral effects of illicit drugs

Book · January 2007

CITATIONS
3

READS
705

5 authors, including:



Jeroen A J Schmitt
Agency for Science, Technology and Research (A*STAR)
55 PUBLICATIONS **2,532** CITATIONS
SEE PROFILE



Kim P. C. Kuypers
Maastricht University
127 PUBLICATIONS **2,384** CITATIONS
SEE PROFILE



Johannes G Ramaekers
Maastricht University
311 PUBLICATIONS **8,944** CITATIONS
SEE PROFILE



Wim J Riedel
Maastricht University
149 PUBLICATIONS **7,250** CITATIONS
SEE PROFILE

Some of the authors of this publication are also working on these related projects:

Drug effects on false memories in a legal context View project

Predicting Risk of Emerging Drugs with In silico and Clinical Toxicology (PREDICT) View project

All content following this page was uploaded by Wim J Riedel on 31 October 2016.

The user has requested enhancement of the downloaded file.

Performance and Behavioral Effects of Illicit Drugs

Jeroen A.J. Schmitt, Caroline T.J. Lamers, Kim P.C. Kuypers, Johannes G Ramaekers, Wim J Riedel

Experimental Psychopharmacology Unit

Brain and Behaviour Institute

Maastricht University

Maastricht, The Netherlands

INTRODUCTION

Abuse of illicit drugs is a widespread problem in society. In the year 2004 over nineteen million Americans were current illicit drugs users, defined as having used an illicit drug at least once in the past month, representing almost 8 percent of the population above twelve years of age (Substance Abuse and Mental Health Services Administration 2005). The term illicit drugs refers to a variety of compounds such as marijuana, cocaine, amphetamines, heroin, and various hallucinogens, including PCP and LSD, which are generally obtained through illegal channels. In addition, drug abuse also includes the non-medical use of prescription drugs, such as tranquillizers and sedatives, medicinal stimulants and analgesics, as well as the abuse of psychoactive compounds found in common household or industrial products (e.g. inhalants). Alcohol and nicotine, although illegal for youths, are not considered illicit drugs.

Illicit drugs can impair behavior and mental performance in various ways. They may cause sedation or over-activation. They can blur or distort perception, compromise a clear judgment of situations, impair decision-making and responding. The behavioral toxicity of a drug can be ascertained through a variety of methods, ranging from subjectively reported experiences to various kinds of epidemiological surveys and controlled experimental studies. Adverse behavioral effects may even be predicted solely on the basis of a drug's pharmacological properties (Riedel et al. 1998). Each method has its advantages and limitations. The

assessment of drug-induced changes with laboratory tests of specific cognitive and psychomotor functions in a controlled and supervised setting may have limited predictive value for real-life complex behaviors, such as driving (Moran 1999). Conversely, with a methodologically sound experimental design, any observed effects can be attributed to a clear factor, notably the administered drug, thus establishing a direct causal link between performance and use of a drug at a certain dose. Causality is particularly difficult to ascertain in cross-sectional epidemiological studies comparing groups of drug abusers to normal controls, since the influence of factors other than drug use is unknown. For example, pre-existing differences in characteristics and life-style cannot be excluded as potential discriminating factors.

The combined picture emerging from various viewpoints and research lines can provide insight into a drug's potential behavioral toxicity. Unfortunately, for many drugs, and particularly for illicit drugs, the data on effects on mental performance and potential risk are incomplete. Existing data are limited to narrow dose ranges, selected research subjects (often young healthy volunteers) and specific behavioral outcome parameters. Although effects in other circumstances may be inferred based on existing information, the actual demonstration of such behavioral effects, for example on driving capacity, remains essential.

This chapter provides an overview of the known behavioral and performance effects of the most commonly abused illicit drugs, with emphasis on driving ability. It will focus on the effects of acute drug intoxication, occurring at the time when the psychoactive substance is present in the body and exerting its pharmacological effects in the central nervous system (CNS). The long-term sequelae of drug abuse as behavioral changes that are the result of structural and irreversible brain damage from long-term exposure to neurotoxic compounds do not fall within the scope of this chapter. The cognitive, emotional and social effects of prolonged drug abuse are addressed in reviews, articles and book sections on various illicit drugs, e.g. cocaine (Nnadi et al. 2005; Verdejo Garcia et al. 2004), ecstacy (Gouzoulis Mayfrank and Daumann 2006; Montoya et al. 2002; Verdejo Garcia et al. 2004), amphetamines (McCann and Ricaurte 2004; Ornstein et al. 2000; Simon et al. 2000), marijuana (Ameri 1999; Hall 2006; Lundqvist 2005; Verdejo Garcia et al. 2004), inhalants (Cairney et al. 2002; Rosenberg et al. 2002; Uzun and Kendirli 2005), hallucinogens (Doering Silveira et al. 2005; Halpern and Pope 1999; Jansen 2000) and opiates (Darke et al. 2000; Davis et al. 2002; Verdejo Garcia et al. 2004).

PSYCHOSTIMULANTS

Psychostimulants boost the users' confidence and temporally enhance feelings of well being and euphoria. The fatigue-counteracting capability of these drugs also make them very popular among truck drivers and others who perform demanding jobs (Crouch et al. 1993). The three most used psychostimulants are cocaine, amphetamines (including methamphetamine) and ecstasy. Cocaine was the first widely used psychostimulant. Amphetamines soon followed, and different amphetamine analogues became available, including methamphetamine and dextro-amphetamine. Amphetamines are often used as a substitute for cocaine. The effects are similar, but amphetamines are cheaper and more available, and their effects are longer lasting. Ecstasy is popular among people in the dance and club scene. Ecstasy can rely for its effect on several derivatives, including MDA and MDE, but the original psychoactive substance of the drug, MDMA, is still the most popular.

COCAINE

Cocaine raises levels of the neurotransmitters dopamine and norepinephrine by inhibiting their reuptake into presynaptic terminals and to a lesser degree by acting as direct agonists. The influence of cocaine on the dopamine system seems to play a prominent role in the drugs' psychostimulant properties (Feldman et al. 1997; Gawin 1991; Izenwasser 1998).

Cocaine increases pulse rate, body temperature, glucose availability, pupil size, vasoconstriction, alertness, motor activity and restlessness and it counteracts sleep (Rush et al. 1999; Stillman et al. 1993). The drug heightens energy levels and enhances consciousness, talkativeness, feelings of euphoria and self-confidence (Higgins and Katz 1998). The cocaine "high" often is followed by a fatigue rebound with a period of anxiety, depression and paranoia (Higgins and Katz 1998). After higher doses, tremors, convulsions and a severe loss of coordination can occur (Feldman et al. 1997). High doses also can produce sleeplessness, anxiety, paranoia, psychosis, hypervigilance, hyperreactivity, increased impulsivity, compulsive behaviour and increased aggression (Higgins and Katz 1998; Licata et al. 1993).

Cocaine administration under experimental conditions has produced contrasting findings. Some investigators reported improved reaction time, performance speed, impulse control, enhanced attention and information processing (Farre et al. 1993; Higgins et al. 1990; Higgins et al. 1993; Johnson et al. 1998) (Fillmore et al. 2005; Stillman et al. 1993). Others found no effect of a single dose of cocaine on information processing, learning, recognition memory, simple and choice reaction time, concentration, and central nervous system processing capacity (Farre et al. 1993; Foltin et al. 1993; Higgins et al. 1990; Johnson et al. 1999; Rush et al. 1999).

Combined use of cocaine and alcohol is very common among cocaine abusers (Grant and Harford 1990). When cocaine and alcohol have been administered together under experimental conditions, cocaine compensated for impaired task performance that was observed with alcohol alone, including reaction speed and information processing (Farre et al. 1993; Higgins et al. 1993).

The influence of cocaine on driving performance has not been studied. In traffic situations, however, increased self-confidence, impulsivity and aggression could result in overestimation of one's driving performance and higher risk acceptance. Another expected problem for adequate driving performance is the rebound of sleep during withdrawal. In this stage, cocaine abusers can experience extreme fatigue, lack of concentration and anxiety. This impairs focus of attention, and therefore would impair driving performance. A combination of cocaine and ethanol use has been frequently identified in fatally injured drivers (Marzuk et al. 1990). This finding suggests that the reduction of alcohol-induced sedation does not lead to safer driving performance.

AMPHETAMINE

Amphetamine acts to release newly synthesized dopamine and norepinephrine and inhibit their reuptake (King and Ellinwood 1997). Under experimental conditions, small doses of amphetamines (5-20 mg) have been shown to increase arousal and improve task performance in fatigued, as well as non-fatigued, subjects. The effects include increases in reaction speed, vigilance, accuracy in a spatial delay response task, verbal reasoning, coordination and cognitive processing speed (Fleming et al. 1995; Koelega 1993; Newhouse et al. 1989). Enhanced memory was observed after 10 mg *d*-amphetamine due to improved consolidation of new

material (Soetens et al. 1995). Data from other studies, however, show that amphetamines did not affect task performance, including information processing and mental set shifting (Pickworth et al. 1997). The amounts administered in experiments resemble therapeutic dosages (2.5-60 mg), but amphetamine abusers often take much higher doses (50-300 mg) and multiple doses (Logan 1996; Newhouse et al. 1989; Pickworth et al. 1997).

In one study, methamphetamine abusers had used their regular dose of the drug during the seventy-two hours prior to assessment (Simon et al. 2000). The exact time between drug consumption and assessment was not given, but only 55 percent of subjects reported using methamphetamine on the day of assessment. Therefore, many subjects possibly were in withdrawal while being tested. They had problems manipulating information and were less able to combine information in new ways. They also had difficulty focusing on the task at hand, because they lacked the capacity to ignore irrelevant information. These observed impairing effects may indicate either reduced processing resources or reduced processing rate (Simon et al. 2000).

Silber et al (2005) (Silber et al. 2005) assessed the acute effects of dexamphetamine on simulated driving performance of 24 volunteers in a double blind, placebo controlled, cross-over design. Mean dexamphetamine blood concentrations were 83 ng/ml and 98 ng/ml at 120 min and 170 min post drug, respectively. Results indicated a decrease in overall simulated driving ability following dexamphetamine administration during the day-time but not the night-time scenario tasks. Contributing to this performance reduction, "incorrect signalling", "failing to stop at a red traffic light" and "slow reaction times" were the behaviours most strongly affected by dexamphetamine

Methamphetamine abusers admitted to trauma centres were most likely to have been injured in traffic accidents, whereas cocaine abusers' primary causes for admission were injuries caused by violence, such as gunshot or stab wounds and assaults (Schermer and Wisner 1999). This does not necessarily indicate safer driving after cocaine, in comparison to methamphetamine. Instead, it may reflect a relatively higher rate of traffic participation after the use of methamphetamine as seems to be confirmed by field studies. Although only two percent of voluntarily tested truck drivers tested positive for methamphetamine, twelve percent refused participation. The actual number of questioned truck drivers who had used methamphetamine, therefore, may be higher (Lund et al. 1988). In another study, methamphetamine was found in seven percent

of fatally injured truck drivers (Crouch et al. 1993). Complex behavioral tasks, such as driving, require rapid processing of incoming information and correct decision making in regard to other traffic and traffic signaling. Thus, incorrect or slowed information processing can be expected to reduce traffic safety.

Other impairing effects of amphetamines during withdrawal include extreme exhaustion (amphetamine abusers can go without sleep for up to a week), loss of concentration, paranoia and anxiety (Logan 1996). Typical amphetamine-related driving behaviors, which lead to arrest, accidents, or fatal car crash, include drifting in and out of lane of travel, weaving, drifting of the road, speeding, high speed collisions and erratic driving (Logan 1996).

In conclusion, a therapeutic dose of amphetamine will generally not severely reduce task performance and traffic safety. High doses, however, can impair driving performance during the acute phase by inducing hallucinations, panicky behavior and increased risk taking. During withdrawal the reduced capacity to ignore irrelevant information, manipulate and combine information, together with extreme exhaustion and confusion, mediate misinterpretation of information, wrong decision making, reduced attention, risk taking and dangerous driving.

ECSTASY

± 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a phenethylamine, structurally related to amphetamine and mescaline (De Man 1994; Morgan 2000). MDMA is a monoaminergic agonist that releases and inhibits reuptake of serotonin (White et al. 1996) and to a lesser extent of dopamine (Colado et al. 2004).

In some studies, single doses of MDMA (range 0.9 – 1.9 mg/kg) were not found to impair task performance, including selective attention, visual search, planning or retrieval from semantic memory (Downing 1986; Vollenweider et al. 1998a). In a study with MDMA doses of 75 and 125 mg, esophoria (squinting) was observed after the higher dose but there was no effect on simple reaction time (Cami et al. 1999). Several experimental have studies reported that single doses of MDMA (75-100 mg) produce stimulant effects and may improve tracking performance in laboratory and on-the-road driving tasks, movement speed and impulse control (Kuypers and Ramaekers 2006; Lamers et al. 2003; Ramaekers and Kuypers 2006;

Ramaekers et al. 2006a). Yet, these same studies have also reported detrimental effects of MDMA on timing ability, brake reaction time and verbal and spatial memory function that may be of crucial importance in traffic. In addition impaired coordination, concentration difficulties and hallucinations have been observed in people while under the influence of MDMA (Downing 1986; Schifano 1995; Vollenweider et al. 1998a).

Any cognitive or psychomotor impairment can compromise driving performance. Therefore, any combination of the observed impairing effects of MDMA is likely to seriously impair driving performance. The drug's use has already been linked to sometimes fatal car crashes (Henry et al. 1992; Moeller and Hartung 1997; Mørland 2000; Schifano 1995). Furthermore, in real life, MDMA doses may be higher than those administered under experimental conditions, and it may be combined with sedative psychoactive substances such as marijuana and alcohol. Experimental studies on combined use of MDMA and alcohol have without exception indicated that the stimulant effects of MDMA do not mitigate the impairing effects produced by alcohol on actual and simulated driving performance, impulse control and psychomotor performance (Hernandez-Lopez et al. 2002) (Brookhuis et al. 2004; Kuypers et al. 2006; Ramaekers and Kuypers 2006). The lack of mitigating effects of MDMA on alcohol induced impairment on measures of impulsivity or risk tasking and actual driving may be of particular importance in terms of road safety issues since most of the MDMA-impaired driving cases that have been reported in the scientific literature consist of drivers who have taken multiple drugs and/or alcohol (Logan and Couper 2001). In conclusion, the driving skills of persons under the influence of MDMA may be seriously impaired as indicated by its detrimental effects on time estimation, break reaction time, perception and memory functions.

CANNABIS

Cannabis sativa contains more than 400 chemical compounds, of which about sixty are cannabinoids. The cannabinoid primarily responsible for the drugs' physiological and psychological effects is Δ^9-tetrahydrocannabinol (THC). When entering the systemic circulation, THC is rapidly distributed in fatty tissues, including the brain, and full elimination from the body can take several days to weeks. Consequently, THC metabolites can be present in urine for an extended period after the last drug intake. To date, two cannabinoid receptors, CB_1 and CB_2, have been identified. Cannabinoid receptors are involved in analgesia,

cognition, memory, motor activity, control of appetite and vomiting. THC is generally used for recreational purposes because of its psychotropic properties, but it is also indicated in the medical treatment of pain, inflammation, glaucoma and the nausea associated with cancer therapy (Voth and Schwartz 1997).

THC is rapidly absorbed during cannabis smoking and its peak effects appear after thirty to sixty minutes. Acute subjective effects are dose dependent, and their duration is two to four hours. Subjectively, the principal psychological effect of THC is euphoria or a "high". This state is sometimes accompanied by a mild state of anxiety, tension and confusion. Acute consumption of cannabis is associated with impairment of a variety of cognitive and psychomotor tasks, including memory, sense of time, motor coordination, and reaction speed. Memory impairment is the most consistently reported cognitive deficit. The acquisition or consolidation of newly learned information and work seems particularly impaired after an acute dose of THC (Ameri 1999; Robbe 1994).

Numerous experimental studies have investigated the effects of THC on isolated psychological functions and skills related to driving performance. These have generally shown that THC amounts between 40 and 300 µg/kg cause a dose dependent reduction in performance on laboratory tasks of attention, reaction time, tracking, or motor control (Robbe 1994). Results from driving simulator and closed-course studies of THC doses up to 250 µg/kg have generally failed to demonstrate severe effects (Attwood et al. 1981 ; Casswell 1977 ; Peck et al. 1986; Smiley et al. 1981; Stein et al. 1983). Results of these studies have shown differences between the effects of alcohol and the effects of THC. Alcohol leads to an increase in driving speed whereas THC leads to a decrease in speed. THC subjects drive in a more conservative manner, i.e., in the studies, they maintained a longer headway and refused more opportunities to pass, whereas the opposite was the case following alcohol. THC did, however, increase reaction time and the standard deviation of lateral position (SDLP), although the magnitude of impairment was generally small. There were also no significant interactions between alcohol and marijuana effects on performance, indicating that the combined effects of the drugs are additive.

A series of driving studies in actual traffic was conducted by a group of researchers at Maastricht University, The Netherlands. Robbe (1998) (Robbe 1998) investigated the effects of THC 0, 100, 200 and 300 µg/kg on performance in a one-hour road-tracking test and a thirty-minutes car-following test on a primary highway,

and the effect alcohol and THC 100 µg/kg on a city driving test. The combined effects of THC and alcohol were further investigated in two subsequent studies with subjects who were recreational users of marijuana. The first assessed the effects of THC 0, 100 and 200 µg/kg with and without a low dose of alcohol on road tracking and car-following performance (Ramaekers et al. 2000; Robbe 1998). In the second study, during a city driving test a licensed driving instructor used a standardized questionnaire to rate the effects of THC 0 and 100 µg/kg with and without a low alcohol dose (BAC <0.05 g/dl) on general driving proficiency (Lamers and Ramaekers 2001). In addition, the subjects' visual search for traffic at intersections was recorded by means of head-mounted cameras that registered the subject's eye and direction of gaze.

In these studies, THC produced a dose related increment in SDLP, which is a measure of "weaving", during the road-tracking test. Reaction time to the speed accelerations/ decelerations of a lead vehicle in the car-following test and general driving proficiency in the city driving test were not affected by THC. Blood concentrations of THC and THC-COOH were not related to the degree of impairment. The effects of THC on SDLP were comparable to those of alcohol at a BAC of 0.05 g/dl, the legal limit for driving in most European countries. THC in combination with a low dose of alcohol, however, produced severe performance impairment in the road-tracking test, and to lesser extents also in the car-following and city driving test. There were no significant interactions between alcohol and THC, indicating that the effects were additive. When compared to a previously established alcohol calibration curve (Louwerens et al. 1987), the combination of THC 100 and 200 µg/kg with alcohol produced a rise in mean SDLP equal to that associated with BACs of 0.09 g/dl and 0.14 g/dl, respectively.

Epidemiological studies have generally failed to establish an association between crash risk and driving under the influence of cannabis. Yet, most epidemiological surveys have established cannabis use among crashed drivers by determining the presence of an inactive metabolite of THC in blood or urine (Ramaekers et al. 2004). Unfortunately, this metabolite can be detected in body fluids for days after smoking and can only be taken as evidence for past use of cannabis. Recent use of cannabis can only be established by directly measuring THC in blood. The latter procedure was followed in only a few epidemiological surveys (e.g. (Drummer et al. 2004; Laumon et al. 2005). These surveys showed that THC positives are 2-6 times more likely to be responsible for their crash as compared to cases that had not used drugs or alcohol.

Significant odds ratios (OR) of crash risk for THC concentrations ranging between 1-2 ng/ml and 2-5 ng/ml in whole blood were 1.45 and 2.13 respectively (Laumon et al. 2005). At THC concentrations > 5 ng/ml in whole blood the ORs ranged from 2.1-6.6 (Drummer et al. 2004; Laumon et al. 2005). When converted to THC concentrations in serum their equivalents would be 2-4, 4-10 and >10 ng/ml respectively. These ranges correspond well with limits of impairment as established in a recent experimental study on the effect of THC on perceptual motor control, motor impulse control and cognition (Ramaekers et al. 2006b). In the latter study, slight and selective impairment of tracking performance was notable at THC ranges between 2-5 ng/ml, but impairments became truly prominent across all performance domains at serum THC concentrations between 5-10 ng/ml. These data support epidemiological data and show that THC serum concentrations between 2-5 ng/ml establish the lower and upper range of a per se limit for defining general performance impairment above which drivers are at risk.

In summary, experimental and epidemiological studies indicate that THC impairs driver ability and increases crash risk a dose-related manner. First indications of driver impairment and elevated crash risk in experimental and epidemiological studies were evident for serum THC concentrations > 2ng/ml.

HALLUCINOGENS

A wide variety of pharmacological substances produce so-called hallucinogenic effects. Briefly, a psychiatric definition of a hallucination is 'sensory perception without external stimulus of the relevant sensory organ' (DSM III-R 1987, American Psychiatric Association). In addition, the most important property of a hallucination is its illusory character, the hallucinant believes that the hallucination is a real perception. This should be distinguished from those which could be called hallucinatory experiences of which the percipient is aware that they are unreal. Drug-induced hallucinations are most often visual, such as geometric patterns or haloes around lights. Often, drug users are aware that these effects are produced by the substance taken, so that true drug-induced hallucinations are rare. Perhaps hallucinations induced by other medical conditions are less rare and should always be considered when encountering the problem in actual traffic. This could relate to schziophrenia (usually auditory hallucinations such as hearing voices), psychotic depression, pot-traumatic stress-disorder, fever, delirium, dementia, liver failure, kidney failure or brain cancer.

There are no systematic epidemiological studies of hallucinogen use by drivers or laboratory studies of the effects of hallucinogens on skills related to driving. Visual disturbances while driving, even more than ten hours after drug use, have been reported in individual cases (Woody 1970). Delayed visual hallucinations appearing days to months after the use of LSD potentially could impair driving capacity (Seppälä et al. 1979). High doses of stimulant drugs also frequently cause a sensation of bugs crawling on or immediately under the skin, which may have significant effects on behavior, in partular while driving.

Many substances that are discussed in other sections of this chapter, such as cannabis, amphetamines and MDMA, are said to possess hallucinogenic properties. This, however, appears not to be their primary characteristic. Therefore, this section focuses on substances, which are used primarily for their hallucinogenic effects. They are categorized according to their primary pharmacological mechanisms of action.

GLUTAMATERGIC HALLUCINOGENS (NMDA RECEPTOR ANTAGONISTS)

Phencyclidine (PCP) and ketamine are noncompetitive NMDA glutamate receptor antagonists. PCP can induce a broad range of psychological symptoms in non-schizophrenic subjects that resemble the symptoms observed in schizophrenia (Ellison 1995; Krystal et al. 1994; Oranje et al. 2000), including hallucinations, delusions, idiosyncratic and illogical thinking, poverty of speech and thought, agitation, disturbances of emotion, withdrawal, decreased motivation, and dissociation (Newcomer et al. 1999). Ketamine, a PCP analog still used in human anesthesia, has been reported to cause reactions similar to but not as severe as those caused by PCP, including brief, reversible “positive” and “negative” schizophrenia-like symptoms (Krystal et al. 1994; Newcomer et al. 1999). Both PCP and ketamine can exacerbate the psychosis in schizophrenia (Newcomer et al. 1999).

Ketamine

The most important adverse effects of the anaesthetic ketamine are hallucinations and excessive increases in blood pressure and heart rate (Moran 1999). These reactions can be attenuated or avoided by combining ketamine with sedative or hypnotic drugs (Adams and Werner 1997). A standard recreational dose of

ketamine is typically 1/8 g, usually taken intranasally, with effects lasting for approximately one hour. It is one of the drugs consumed regularly amongst members of the new dance culture. At present, the long-term consequences of ketamine use, including addictive potential, are not known (Moran 1999).

Subanaesthetic doses of ketamine can produce psychedelic effects in healthy volunteers. Several investigators have studied the effects of ketamine in volunteers to model cognitive deficits in schizophrenia, memory impairment and dementia. These studies have shown that NMDA antagonists produce a broad range of symptoms, behaviours, and cognitive deficits that resemble aspects of endogenous psychoses and thought disorder, particularly schizophrenia and dissociative states (Adler et al. 1998; Adler et al. 1999; Bowdle et al. 1998; Breier et al. 1997; Duncan et al. 2001; Hetem et al. 2000; Lahti et al. 2001; Van Berckel et al. 1998; Vollenweider et al. 1997a; Vollenweider et al. 1997b).

Phencyclidine

Phencyclidine (PCP) or "angel dust" is a dissociative anaesthetic with notoriety as an abuse substance. A derivative of the anaesthetic ketamine, PCP is the predominant member of the arylhexylamine class of designer drugs (Buchanan and Brown 1988). States of florid psychosis lasting for days can follow a brief encounter with PCP (Isaacs et al. 1986). Observations of many investigators have shown that the acute effects of PCP following several routes of administration are dose-related (Pradhan 1984). High doses produce acute intoxication with disturbing manifestations including psychosis, numbness, light-headedness, vertigo, ataxia, and nystagmus. Furthermore, some subjects in these studies became irritable, argumentative or negative under conditions of social stress and demanding tasks. In addition to a variety of central actions, PCP has also been shown to affect cardiovascular function, heat storage, and exercise performance. It can also induce, although rarely, psychotic episodes in psychotic and pre-psychotic personalities. Tolerance, but not physical dependence, develops to the effects of PCP. Psychological dependence as indicated by craving for the drug has, however, been reported. The elicitation of violent of psychotic behaviour by phencyclidine is well documented (Moran 1999).

SEROTONERGIC HALLUCINOGENS

The classical hallucinogens, such as LSD, DMT, mescaline or psilocibin, are all characterised by a serotonergic pharmacology; all display agonist activity at 5-HT_2 receptors, and there is evidence that some may interact with other 5-HT receptor subtypes as well, such as 5-HT_{1A} receptors (McKenna 1996). Chemically they tend to fall into one of three categories: phenylethylamine derivatives (mescaline and synthetic analogues), lysergamides (LSD, morning glory seeds) and tryptamine derivatives (psilocybin, psilocin, DMT) (McKenna 1996).

Lysergide

Lysergide (LSD), familiarly called "acid", is the synthetic version of ergotamine, produced by ergot, which is a parasite of rice or rye (Maes et al. 1999). It is the diethylamide of lysergic acid. After its discovery, LSD was misused very quickly for its hallucinogenic effects, because the active dose of this hallucinogenic is so small that the drug can be delivered in many forms, including microtablets, window pane, or stamps (Maes et al. 1999).

The most likely mechanism to account for LSD-induced hallucinations is the increase of neocortical glutamatergic neurotransmission through an initial partial agonistic action at 5-HT_2 receptors, predominantly 5-HT_{2A} receptors (Aghajanian and Marek 1999). The effects appear fifteen minutes to one hour after ingestion, and can last six to eight hours. Tolerance develops after only a few days of use. Cardiac frequency, blood pressure and temperature increase, and spatiotemporal distortion and depersonalization are frequently reported. Reaction time is significantly increased. Users can become so fearful that they will make suicide attempts. LSD induces a solid psychic dependence (Maes et al. 1999).

Magic mushrooms: psilocybin and psilocin

Magic mushrooms belong essentially to three groups: psilocybe, panaeolus and conocybe. The psychoactive hallucinogenic substances are psilocybin and psilocin, chemically similar to LSD. Effects can be obtained with 10 to 60 mg, and can last five to six hours. First, the user will be affected by nausea, and then sensations affecting eyes, hearing and consciousness occur. These products seem to induce less panic than LSD (Maes

et al. 1999), but their effects are similar. With psilocibin, 5-HT_{2A} agonism has been demonstrated as the mechanism to induce symptoms (Vollenweider et al. 1998b).

Ayahuasca (DMT)

Ayahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N- dimethyltryptamine (DMT) (Riba et al. 2001). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America, and is presently gaining the attention of psychedelic users in North America and Europe. Tea brewed of encapsulated freeze-dried ayahuasca in a dose range of 0.5, 0.75, and 1.0 mg DMT/kg body weight, produces psychological effects including hallucinatory sensations. The effects begin within thirty to sixty minutes, peak between sixty and 120 minutes, and last until about 240 minutes. Ayahuasca effects are of longer duration and milder intensity than those previously reported for intravenously administered DMT. DMT and hence ayahuasca, like LSD, has affinity for 5-HT_{2A} receptors (Riba et al. 2001).

Mescaline (peyotecactus Lophophora Williamsii)

Mescaline is the active compound extracted from the peyote, a cactus from Central America. The chemical structure is 3,4,5-trimethoxy-phenethylamine. After oral ingestion, 66 percent can be absorbed (Maes et al. 1999). The effects are very similar to LSD, with reinforcement of color visions. Users call mescaline the “mellow LSD”, but real hallucinations are more frequent than with LSD. Tachycardia, hypertension, hyperthermia, hypersalivation and tremor are the most frequent side effects. Mescaline induces tolerance and psychic dependence, and may sometimes produce physical dependence (Maes et al. 1999). Synthetic derivatives of phenethylamine are substances like DOM (2,5-dimethoxy-4-methylamphetamine), and MDA (3,4-methylenedioxyamphetamine) that are structurally similar to the amphetamines (Christophersen 2000).

HALLUCINOGEN EFFECTS ON DRIVING PERFORMANCE

The incidence of the use of hallucinogens is not well documented. Taken from a database containing 44,000 records of persons registered in an addiction care unit in The Netherlands, it appeared that there were twenty-

nine cases reporting frequent LSD use. For comparison: 328 reported frequent use of MDMA (De Bruin et al. 1998).

There are no data from studies of hallucinogens effects on driving behaviour, but the many observations from experimental studies with healthy volunteers provide evidence that hallucinogen use and traffic participation do not mix in a safe manner. The reason for this is the primary motive for the use of hallucinogenic substances, which is the deliberate desire to experience an altered or distorted perception of reality.

INHALANTS

The term inhalants refers to a broad range of gases and vapors that can be inhaled to induce a psychoactive or mind-altering effect. Inhalants are inexpensive, readily available, and often abused by children, adolescents and young adults (Kurtzman et al. 2001). Based on their pharmacological and behavioral effects, they can be categorized in three main groups: (1) volatile solvents and fuels, (2) nitrous oxide and (3) alkyl nitrites (Balster 1998).

VOLATILE SOLVENTS AND FUELS

Volatile solvents are liquids that vaporize at room temperature. They are abundantly found in household and industrial products, including thinners, paint, nail polish remover, and correction fluids (acetone, toluene, methylene chloride, methanol), dry-cleaning fluids and degreasers (tetrachloroethylene, trichloroethane), gasoline and glues (toluene, hexane, ethyl acetate, trichloroethylene), and felt-tip marker fluids (toluene). Aerosols, including hairspray, deodorants and air fresheners, contain propellants (propane, butane, fluorocarbons [“freons”]), whereas paint and shoeshine sprays may contain solvents (toluene).

The majority of solvents have behavioral effects that are similar to that of the classic CNS depressants, i.e. alcohol, barbiturates and benzodiazepines (Balster 1998; Bowen et al. 1996a; Evans and Balster 1991). The neuronal mechanisms underlying the CNS effects have not yet been fully identified, but they may include enhancement of GABA and inhibition of NMDA neurotransmission (Balster 1998). Inhalation of solvents produces a very rapid intoxicated state that resembles alcohol intoxication in many respects (Bowen et al.

1996a; Bowen et al. 1996b; Sharp and Rosenberg 1997) including the psychomotor and cognitive effects (Echeverria et al. 1991). The symptoms include initial excitation turning to drowsiness, euphoria, disinhibition, lightheadedness and agitation. Increasing intoxication can lead to ataxia, slurred speech, delusions, dizziness and disorientation, and further intoxication may induce signs of sleeplessness, general muscle weakness, nystagmus and occasionally hallucinations (Dinwiddie 1994; Kurtzman et al. 2001; Sharp and Rosenberg 1997). In extreme cases, stupor typically develops and may progress to seizures, coma, cardiopulmonary arrest or, not uncommonly, death. Abusers may feel invulnerable and engage in high-risk, impulsive behaviors (Sharp and Rosenberg 1997).

Although intoxication is characterized by a rapid onset and equally rapid recovery, a ”high” can be maintained for several hours by repeated sniffing (Meredith et al. 1989). As a result, performance may be impaired for extended periods of time may thus present a safety hazard. To illustrate the potential risk, almost a quarter of related fatalities studied in Virginia were reported to be associated with sniffing while driving, riding or sitting in a motor vehicle (Bowen et al. 1999). Specific cases where car accidents were associated with the use of the propellant difluorethane (Broussard et al. 1997), the anaesthetic enflurane (Musshoff et al. 2002) and methylene chloride (Brewer et al. 1997) while driving have also been reported. Therefore, although no experimental data are available on solvent intoxication and driving capacity, impairment of performance that is qualitatively and quantitatively comparable to that of alcohol may be expected.

NITROUS OXIDE

Nitrous oxide or “laughing gas” is the most abused of the gases. Because nitrous oxide is commonly used as an analgesic in medicine and dentistry, medical personnel sometimes abuse it. It is also used as a propellant in whipped cream dispensers.

There is a wealth of information documenting that extended nitrous oxide inhalation (minutes to more than an hour), as used for anesthetic purposes, impairs psychomotor and cognitive functioning (Armstrong et al. 1995; Cheam et al. 1995; Fagan et al. 1994; File et al. 1992; Janiszewski et al. 1999; Walker and Zacny 2001; 2003; Zacny et al. 1994a; Zacny et al. 1999). A recent study compared effects on driving performance

in 20 knee arthroscopy surgery patients before and at 2h and 24h after general anesthesia using nitrous-oxide+oxygen to maintain anesthesia after induction with a number of other agents such as midazolam, propofol and fentanyl. Patients showed lower alertness levels and impaired driving skills preoperatively and 2 h postoperatively. Based on driving simulation performance and subjective assessments, authors concluded that patients are safe to drive 24 h after general anesthesia (Chung et al. 2005).

Nitrous oxide is most commonly abused via inhalation of higher concentrations for a very brief period of time (i.e., one or several breaths). The behavioral effects, including those on psychomotor performance, peak approximately thirty seconds after bolus inhalation and gradually subside over the time course of about five minutes. Nonetheless, even brief inhalation (four breaths) of 80 percent nitrous oxide has been shown to produce memory deficits as well as psychomotor impairment. Higher concentrations of nitrous oxide (100 percent) produce hypoxia, which may also add to the behavioral sequelae (Zacny et al. 1994b).

ALKYL NITRITES

Alkyl nitrites act primarily to dilate blood vessels and relax smooth muscle tissue through the release of endogenous nitric oxide. Most abused compounds are amyl nitrite (used medically for the treatment of angina), butyl nitrite and cyclohexyl nitrite. The latter is present in room odorizers, whereas amyl nitrite and butyl nitrite are sold in ampules or bottles and are called ”poppers”, “snappers” or “rush”. Alkyl nitrites are used as a euphoriant and as a sexual enhancer (Chalmers 1991). The use of nitric inhalants can acutely produce dizziness and headache from orthostatic hypotension. Nitrites increase global cerebral blood flow, and have been noted to decrease anger, fatigue and depression (Mathew et al. 1989). As with solvents and alcohol, biphasic effects on activity (activation followed by inactivation at higher dosages) are seen with amyl nitrite in animal studies (Bowen and Balster 1998). Users report a variety of short-term effects that are consistent with CNS depression, including lack of coordination and balance, blurred vision, short-term memory loss, and lethargy (French and Power 1997).

OPIOIDS

The opioids are a group of compounds that includes natural opium derivates (morphine and codeine), semisynthetic substances, the most notorious being heroin (diacetylmorphine), and synthetic drugs. The characteristics common to all opioids is that they exert their action by binding to specific opioid receptors, which are widely distributed throughout the brain and peripheral nervous system. Three main receptor subtypes have been identified; mu, delta and kappa receptors (Reisine and Pasternak 1996). Based on their affinity and actions on these receptors, opioids can be categorized into prototypical mu-agonists (morphine, heroin, methadone), partial mu-agonists (codeine) and mixed agonists-antagonists (buprenorphine) (Jaffe and Martin 1990; Zacny 1995).

Opioids are potent analgesics and opioid drugs are extensively used for the management of moderate to severe pain, and chronic pain in cancer patients (Breivik 2005; Joranson et al. 2000). They produce altered mood (often euphoria), decreased anxiety, respiratory depression, inhibition of gastrointestinal motility, inhibition of certain spinal reflexes, suppression of cough and a reduction of pupil size (miosis). They can also produce pruritus (itching), nausea and vomiting (Jaffe et al. 1997). The development of tolerance and physical dependence is a classic feature of all opioid drugs (Reisine and Pasternak 1996).

The primary opioid drug of abuse is heroin. However, among medical professionals who have readily access to them, other morphine-like agonists such as fentanyl and meperidine may also be abused. Methadone, a morphine-like agonist, is used to treat heroin abuse. Its longer action, availability as an oral preparation, and ability to blunt the craving for other opioids make methadone the most effective treatment for opioid abuse currently used.

The current general consensus with regard to the cognitive and psychomotor effects of opioids is that, while some impairment of performance may occur following a single administration, the debilitating effects soon wear off with continued administration of a fixed dose. Sudden dose increments may result in the temporary reappearance of impaired performance. For example, Bruera et al. (Bruera et al. 1989) demonstrated that after receiving their opioid medication (usually morphine or hydromorphone) cancer patients on stable opioid therapy experience no performance decrements, whereas patients who had a dose increment of at least 30 percent in the last three days showed impaired psychomotor, memory and arithmetic performance compared to pre-drug assessments.

Tolerance usually develops within days and sedative effects continue to decline within the first three weeks of opioid treatment (Kress and Kraft 2005). As a result, people who are on stable doses of opioids for an extended period of time, show little if any treatment-related cognitive impairment (Zacny 1995; Zacny 1996b). Patients who are on chronic opioid therapy, including methadone treatment for heroin abuse, are in principle considered fit to drive and work, (Byas Smith et al. 2005; Chapman 2001; Galski et al. 2000; Hanks et al. 1995; Kress and Kraft 2005; Smith 1996; Vainio et al. 1995; Zacny 1996a), although it is recommended that driver fitness is evaluated and monitored on a individual basis (Kress and Kraft 2005). In an extensive review of studies that have examined performance levels of patients on stable doses of opioids (Fishbain et al. 2003), it was concluded that the majority of studies indicated that opioids do not impair driving-related skills in opioid-dependent patients. Based on AHCPR (Agency for Health Care Policy Research) criteria, the evidence for no impairment was considered consistent for psychomotor functioning, actual driving performance (on/off road and simulators) and epidemiological data on stable opioid users and accident risk, motor vehicle violations and convictions. The evidence for cognitive impairment was inconclusive (Fishbain et al. 2003).

MORPHINE

Identification of the cognitive and psychomotor effects of opioid drugs is largely based on studies with morphine. A comprehensive review of these studies, dating back to the 1940s 1950s and 1960s, was published by Zacny (1995). In opioid-naive healthy volunteers, morphine in acute dosages up to 30 mg has been shown to impair a variety of functions, including reaction time, tracking, information processing, attention, and memory (Cleeland et al. 1996; Hanks et al. 1995; Walker and Zacny 1999; Zacny 1995; Zacny et al. 1998). This broad pattern of impairment is consistent with a mild dearousing effect (sedation), which is also apparent from subjective reports of mental clouding, confusion, grogginess and light-headedness. Generally, speed rather than accuracy is reduced (Zacny 1996a). It must be noted that the observed detrimental effects are generally very mild when compared, for example, to those of low dosages of benzodiazepines (Hanks et al. 1995), and most often performance is found to be unchanged (Hill and Zacny 2000; Walker and Zacny 1998; 1999; Zacny 1995; Zacny et al. 1998; Zacny et al. 1994c) or may even be

improved (O'Neill et al. 2000). As mentioned above, in opioid-dependent users the cognitive effects are even less pronounced as a result of tolerance (Zacny 1995). A recent report however suggests that even the milder slow release oral morphine as substitution treatment for heroin dependency produced significantly poorer psychomotor performance than methadone maintenance treatment. The authors stressed the preliminary status of these results but also pointed to its potential relevance because of the large number of maintenance treatment patients who drive (Giacomuzzi et al. 2005).

HEROIN

Given the highly addictive profile of heroin, major ethical objections prevent studies of it in an experimental setting. Hence, scant experimental data are available on the performance effects of heroin. Nevertheless, two remarkable studies conducted in the early 1960s describe the effect of both acute and sub-chronic administration of heroin in non-dependent opioid abusers (Fraser et al. 1963; 1964). The subjects were incarcerated men with a history of opioid abuse, but they were not dependent at the start of the experiment. In the two double-blind experiments, the subjects initially received placebo (saline) injections for thirty days (phase 1), with an exception of day seventeen, at which time saline was replaced by 8 mg heroin. Psychomotor (eye-hand coordination) performance was somewhat lower compared to the previous day, but performance on a twelve minute number cancellation task was not affected by the acute heroin administration. In the next phase, which lasted sixty days, the subjects received heroin four times a day in a incremental dosing regimen (10 to 95 mg) and became they physically dependent. During this time, psychomotor performance showed a small but significant decline in the first twelve days but returned to normal (phase 1) levels for the remainder of the study. These results demonstrate that, similar to other opioids, i.e. morphine, tolerance develops for the performance degrading effects of heroin.

The scantiness of experimental heroin studies allows no specific statement as to its performance effects. However, there is marked similarity between heroin and morphine in terms of their efficacy and at the mu-receptor, their ability to produce physical dependence. There also is similarity in their subjective, reinforcing and discriminative stimulus effects. Thus, one may predict minimal, if any, impairing effects of heroin in opioid-dependent users (Zacny 1995).

A recent report however suggests that even the milder slow release oral morphine as substitution treatment for heroin dependency produced significantly poorer psychomotor performance than methadone maintenance treatment. The authors stressed the preliminary status of these results but also pointed to its potential relevance because of the large number of maintenance treatment patients who drive (Giacomuzzi et al. 2005).

METHADONE

In a study by Curran et al (Curran et al. 2001), opioid dependent abusers who underwent a methadone treatment programme received their normal dose (10-50 mg) or a doubled dose according to a crossover design. Diminished long-term memory functioning was seen following the double dose but not the normal dose. Information processing, attention, and psychomotor speed remained unchanged. Reviewing the experimental data, Zacny (1995) concluded that orally administered doses used for methadone maintenance would not impair cognitive or psychomotor performance. Again, in nonusers (Rothenberg et al. 1977) and in users following a sharp dose increase, there is a greater risk of mild impairment.

Recent findings suggest that current methadone users do exhibit a reduction in certain cognitive functions compared to normal, non-drug abusing controls (Darke et al. 2000; Mintzer and Stitzer 2002; Specka et al. 2000). Since methadone maintenance patients typically have a history of prolonged (poly)drug abuse, it remains uncertain whether cognitive impairment is actually attributable to methadone treatment, or the result of for example structural brain damage due to prolonged opioid drug abuse, concomitant alcohol abuse or traumatic head injury. In an attempt to control for such confounding factors and hence assess the true effects of methadone therapy on cognition, Vendejo et al. (2005) compared former heroin abusers with and without methadone maintenance treatment. In this study, methadone maintenance patients showed impaired performance on tests of processing speed, visuo-spatial attention, cognitive flexibility, working memory and analogical reasoning. The authors conclude that methadone consumption itself may impair executive functioning and processing speed (Verdejo et al. 2005).

A recent study compared the effects of the methadone, buprenorphine and levo-alpha-acetyl-methodol (LAAM), as used in maintenance pharmacotherapy for heroin dependence, upon simulated driving with and

without alcohol in 3 months stabilized clients and a control group of non-drug-using participants. While alcohol impaired all measures of driving performance, there were no differences in driving skills across the four participant groups. These findings suggest that typical community standards around driving safety should be applied to clients stabilized in methadone, LAAM and buprenorphine treatment. The findings were considered to be important in terms of the widespread implementation of these treatment options in Victoria, Australia, given that a large proportion of pharmacotherapy clients drive (Lenne et al. 2003). These results are somewhat at odds with those of 2 studies reporting that the newer buprenorphine treatment produces significantly less psychomotor and cognitive impairment as measured with tests capturing driving skills, than methadone treatment in heroin dependence patients (Schindler et al. 2004) (Soyka et al. 2005).

In conclusion, impairment of cognitive ability by opioid drugs is not necessarily or specifically linked to absolute dosage levels. Although there appears to be a rather straightforward dose-response relation in drug-naive users (Walker and Zacny 1999; Zacny et al. 1994c), prolonged opioid users become insensitive to the adverse cognitive effects of even quite high fixed doses (Zacny 1995), although some residual impairment may persist. In the practical setting of drug abuse, however, opioid doses for an individual are likely show considerable variation. Heroin content may vary greatly from dose to dose and the prevalence of nonlethal heroin overdose is extremely high (McGregor et al. 1998). This incidental exposure to higher than normal dosages is likely to produce diminished psychomotor and cognitive abilities. Also, in certain specific situations impairment by occur despite apparent habituation. For example under conditions of low light, the miotic effect to which no tolerance develops (Reisine and Pasternak 1996), may impair performance that is dependent on visual acuity, such as night driving. Furthermore, opioids are known to alter mood, attitude and most likely risk assessment, changes which may ultimately result in careless, indifferent and risky behaviour and increase the likelihood of traffic accidents. Epidemiological data, however, do not indicate that opioid use is associated with increased accident risk (Fishbain et al. 2003; Zacny 1995). This supports the notion that stable doses are safe and may indicate that those who abuse opioid are not likely to engage in traffic.

GAMMA HYDROXYBUTYRIC ACID

Gamma hydroxybutyric acid (GHB) is a substance akin to Gamma-Amino-Butyric-Acid (GABA) that is naturally present in mammal species. It is used as an anaesthetic agent, but other indications have been suggested, such as the treatment of insomnia, alcohol and opiates withdrawal, and many cerebrovascular disorders. After oral absorption, the GHB peak is reached in serum after twenty to forty-five minutes, and the half-life is proportional to the amount ingested (more or less twenty minutes). Metabolism occurs in the liver with oxidation in CO_2. Urinary elimination is very limited (1 to 5 percent of the absorbed quantity) (Maes et al. 1999).

GHB is abused for its euphoric, sedative and anabolic (bodybuilding) effects. An "amphetamine like" sensation is obtained after 20 to 30 mg/kg, and with 10 mg/kg, amnesia and muscular relaxation can be observed. GHB is abused for its euphoric effects and is also reported to increase muscle mass and sexual pleasure (Bosman and Lusthof 2003). These properties have led to its use as a rape drug. Physical dependence occurs. Side effects are nausea, vomiting, vertigo, sleepiness, bradycardia, and respiratory depression. Coma and seizures have been reported following GHB abuse. Patients regain consciousness spontaneously within a few hours after ingestion. Ingestion in combination with alcohol or other psychoactive drugs is very dangerous. One of the major concerns with GHB is the narrow range between dosage needed for desired effects and dosage resulting in loss of consciousness or even coma.

In one study, the effects of GHB on human psychomotor performance and subjective feelings important for the safety of skilled performance, such as driving, were investigated (Ferrara et al. 1999). After single doses of 12.5 and 25 mg/kg (therapeutic doses in alcohol addiction treatments), GHB did not induce changes in psychomotor performance and, therefore, the drug did not seem to influence the ability to drive or work (Ferrara et al. 1999). However, repeated reports of the abuse potential of GHB and its use in treating ethyl alcohol addiction indicate that it may play an "agonist-like" role, which means that it should only used under close medical supervision (Ferrara et al. 1999).

A recent study of forensic GHB cases in The Netherlands (blood >5mg/l and urine >10mg/l) included amongst cases of chemical submission (rape drug), cases of driving under the influence (Bosman and Lusthof 2003). GHB was found in 13 cases of driving under the influence. In contrast to the cases of chemical submission, high concentrations of GHB were found, corresponding with observations of extreme

sleepiness or temporary loss of consciousness. Authors expressed their concerns that use of GHB in traffic may be underestimated because its incidence cannot be derived from present routine toxicological data (Bosman and Lusthof 2003).

Couper & Logan (2004) describe a case of a 38 year old man who has been arrested 7 times over an 8 month period for driving under the influence of GHB. Blood GHB concentrations ranged from 44 to 184 mg/L (N = 7, mean 100 mg/L, median 73 mg/L). Overall signs of impairment included erratic driving (severe lane travel, collisions, and near-collisions), slurred speech, disorientation, slow to react, shaking, agitation, unable to focus, poor coordination and balance, poor performance in field sobriety tests, somnolence, and unconsciousness. Despite the single-case aspect, this study provided clear insight that documented concentration ranges of GHB and its analogs are capable of causing severe cognitive and psychomotor impairment and their use is contraindicated for the safe operation of a motor vehicle (Couper and Logan 2004).

CONCLUSIONS

Without exception, all illicit drugs have the potential to impair the cognitive and behavioural skills that allow a person to engage in normal daily activities, such as driving and working. A person's ability to interact optimally with the environment may be compromised by a distorted perception of the world due to the effects of hallucinogens, marijuana or psychostimulant drugs. Miotic or mydriatic effects of opioids and psychostimulants, respectively, prevent optimal adaption to changing environmental light intensities. On a more general level, drugs such as opioids and inhalants produce CNS depressant effects and may cause sedation, leading to reduced accuracy and responsivity as well as overall dysfunction over a wide range of cognitive domains. In contrast, psychostimulants can induce a state of over-activation in which premature and inaccurate responding may occur. In addition, most drugs produce mood and attitude changes, diminish a person's judgment, quality of decision-making and risk assessment, and produces disinhibition. Most notable are the feelings of overconfidence and increased aggression following stimulant abuse and consequent exposure to risky and dangerous situations. Thus, despite their apparent performance-enhancing effects in certain controlled laboratory task, stimulants are likely to reduce performance in real life.

If, and to what extent, impairment will actually occur with a drug is dependent of certain additional factors besides its potential behavioural effects. Drug dosage, of course, is an important determinant as many behavioural effects are dose-dependent. However, the development of tolerance or sensitisation, or metabolic differences leading to unusually high or low blood drug levels, can modify an individual's response to a particular dose. Environmental cues, i.e. the context in which the drug is used, may also play an important role.

It must also be noted that the dosage and purity of a street drug is often unclear, and illicit drug formulations may contain numerous, potentially toxic constituents, the combined effects of which are largely unknown. Furthermore, poly-drug use is a common rather than exceptional practice among drug abusers. Interaction effects between various illicit drugs, as well as co-use of alcohol, can produce additive and potentiated behavioural effects, which are often not investigated and thus are unknown.

Finally, there is a surge of recent studies reporting presence or absence of effects on driving performance by using driving simulators or laboratory tasks mimicking driving skills. We would like to caution for the risk that these studies may indice a false sense of security when they conclude that certain substances do not impair driving simulator performance or psychomotor skills relevant for driving. Although these studies are important as a preliminary screen of the potential for impairing functions that are a prerequisite for driving capacity, they can not be taken to draw firm conclusions about driving impairment, traffic safety or accident risk itself, more than by proxy. For all these reasons mentioned, there is still a need to conduct controlled studies of drug exposure and effect on driving performance in actual traffic.

REFERENCES

Adams HA, Werner C (1997) Vom Razemat zum Eutomer: (S)-Ketamin. Renaissance einer Substanz? [From the racemate to the eutomer: (S)-ketamine. Renaissance of a substance?]. Anaesthesist 46: 1026-42

Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43: 811-6

Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156: 1646-9

Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S

Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-48

Armstrong PJ, Morton C, Sinclair W, Tiplady B (1995) Effects of nitrous oxide on psychological performance. A dose-response study using inhalation of concentrations up to 15%. Psychopharmacology 117: 486-90

Attwood DA, Williams RD, McBurney LJ, Frecker RC (1981) Cannabis alcohol and driving: effect on selected closed-course tasks Alcohol Drugs and Traffic Safety Almqvist and Witsell International Stockholm

Balster RL (1998) Neural basis of inhalant abuse. Drug Alcohol Depend 51: 207-14

Bosman IJ, Lusthof KJ (2003) Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 133: 17-21

Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-8

Bowen SE, Balster RL (1998) A direct comparison of inhalant effects on locomotor activity and schedule-controlled behavior in mice. Experimental and Clinical Psychopharmacology 6: 235-247

Bowen SE, Daniel J, Balster RL (1999) Deaths associated with inhalant abuse in Virginia from 1987 to 1996. Drug Alcohol Depend 53: 239-45

Bowen SE, Wiley JL, Balster RL (1996a) The effects of abused inhalants on mouse behavior in an elevated plus-maze. Eur J Pharmacol 312: 131-6

Bowen SE, Wiley JL, Evans EB, Tokarz ME, Balster RL (1996b) Functional observational battery comparing effects of ethanol, 1,1,1-trichloroethane, ether, and flurothyl. Neurotoxicol Teratol 18: 577-85

Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-11

Breivik H (2005) Opioids in chronic non-cancer pain, indications and controversies. European Journal of Pain 9: 127-130

Brewer WE, Galipo RC, Morgan SL, Habben KH (1997) The confirmation of volatiles by solid-phase microextraction and GC-MS in the investigation of two traffic fatalities. J Anal Toxicol 21: 286-90

Brookhuis KA, De Waard D, Samyn N (2004) Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety. Psychopharmacology (Berl)

Broussard LA, Brustowicz T, Pittman T, Atkins KD, Presley L (1997) Two traffic fatalities related to the use of difluoroethane. Journal of Forensic Sciences 42: 1186-1187

Bruera E, Macmillan K, Hanson J, MacDonald RN (1989) The cognitive effects of the administration of narcotic analgetics in patients with cancer pain. Pain 39: 13-16

Buchanan JF, Brown CR (1988) 'Designer drugs'. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 3: 1-17

Byas Smith MG, Chapman SL, Reed B, Cotsonis G (2005) The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 21: 345-52

Cairney S, Maruff P, Burns C, Currie B (2002) The neurobehavioural consequences of petrol (gasoline) sniffing. Neurosci Biobehav Rev 26: 81-9

Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (1999) Human pharmacology of 3, 4- methylenedioxymethamphetamine ("Ecstasy"): Psychomotor and Subjective Effects. Journal of Clinical Psychopharmacology in press

Casswell S (1977) Cannabis and alcohol: effects on closed course driving behaviour. In: Johnson I (ed) Seventh International Conference on Alcohol Drugs and Traffic Safety, Melbourne Australia

Chalmers EM (1991) Volatile substance abuse. Med J Aust 154: 269-74

Chapman S (2001) The effects of opioids on driving ability in patients with chronic pain. APS bulletin 11

Cheam EW, Dob DP, Skelly AM, Lockwood GG (1995) The effect of nitrous oxide on the performance of psychomotor tests. A dose-response study. Anaesthesia 50: 764-8

Christophersen AS (2000) Amphetamine designer drugs - an overview and epidemiology. Toxicol Lett 112-113: 127-31

Chung F, Kayumov L, Sinclair DR, Edward R, Moller HJ, Shapiro CM (2005) What is the driving performance of ambulatory surgical patients after general anesthesia? Anesthesiology 103: 951-6

Cleeland CS, Nakamura Y, Howland EW, Morgan NR, Edwards KR, Backonja M (1996) Effects of oral morphine on cold pressor tolerance time and neuropsychological performance. Neuropsychopharmacology 15: 252-62

Colado MI, O'Shea E, Green AR (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173: 249-63

Couper FJ, Logan BK (2004) Addicted to driving under the influence--a GHB/GBL case report. J Anal Toxicol 28: 512-5

Crouch DJ, Birky MM, Gust SW, Rollins DE, Walsh JM, Moulden JV, Quinlan KE, Beckel RW (1993) The prevalence of drugs and alcohol in fatally injured truck drivers. J Forensic Sci 38: 1342-53

Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S (2001) Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology (Berl) 154: 153-60

Darke S, Sims J, McDonald S, Wickes W (2000) Cognitive impairment among methadone maintenance patients. Addiction 95: 687-95

Davis PE, Liddiard H, McMillan TM (2002) Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 67: 105-8

De Bruin A, Vuurman EFPM, Riedel WJ (1998) Gedragseffecten van geneesmiddelen en (ll)legale genotmiddelen als risicofactor bij verkeersdeelname: een literatuuroverzicht. Instituut Hersenen & Gedrag, Universiteit Maastricht

De Man RA (1994) Morbiditeit en sterfte als gevolg van ecstacygebruik. Ned Tijdschr Geneeskd 138: 1850-5

Dinwiddie SH (1994) Abuse of inhalants: a review. Addiction 89: 925-39

Doering Silveira E, Lopez E, Grob CS, de Rios MD, Alonso LK, Tacla C, Shirakawa I, Bertolucci PH, Da Silveira DX (2005) Ayahuasca in adolescence: a neuropsychological assessment. J Psychoactive Drugs 37: 123-8

Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-40

Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P (2004) The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 36: 239-48

Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, Efferen TR, Szilagyi S, Stephanides M, Chappell PB, Gonzenbach S, Ko GN, Rotrosen JP (2001) Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25: 72-83

Echeverria D, Fine L, Langolf G, Schork T, Sampaio C (1991) Acute behavioural comparisons of toluene and ethanol in human subjects. Br J Ind Med 48: 750-61

Ellison G (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev 20: 250-267

Evans EB, Balster RL (1991) CNS depressant effects of volatile organic solvents. Neurosci Biobehav Rev 15: 233-41

Fagan D, Paul DL, Tiplady B, Scott DB (1994) A dose-response study of the effects of inhaled nitrous oxide on psychological performance and mood. Psychopharmacology 116: 333-338

Farre M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, Cami J (1993) Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther 266: 1364-73.

Feldman RS, Meyer JS, Quenzer LF (1997) Principles of Neuropsychopharmacology. Sinauer Associates Inc., Sinauer Associates Inc.

Ferrara SD, Giorgetti R, Zancaner S, Orlando R, Tagliabracci A, Cavarzeran F, Palatini P (1999) Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. European Journal of Clinical Pharmacology 54: 821-827

File SE, Balakrishnan J, Murray A, Harris A, Skelly AM (1992) Effects of nitrous oxide on memory for instructions in dental patients. Hum Psychopharmacol 7: 37-44

Fillmore MT, Rush CR, Hays L (2005) Cocaine improves inhibitory control in a human model of response conflict. Exp Clin Psychopharmacol 13: 327-35

Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS (2003) Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 25: 559-77

Fleming K, Bigelow LB, Weinberger DR, Goldberg TE (1995) Neuropsychological effects of amphetamine may correlate with personality characteristics. Psychopharmacol Bull 31: 357-362

Foltin RW, Fischman MW, Pippen PA, Kelly TH (1993) Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug Alcohol Depend 32: 93-106

Fraser HF, Jones BE, Rosenberg DE, Thompson AK (1963) Effects of addiction to intravenous heroin on patterns of physical activity in man. Clinical Pharmacology and Therapeutics: 188-196

Fraser HF, Jones BE, Rosenberg DE, Thompson AK (1964) Effect of a cycle of addiction to intravenous heroin on certain physiological measurements. Bulletin of Narcotics 16: 17-23

French RS, Power R (1997) Self-reported effects of alkyl nitrite use: A qualitative study amongst targeted groups. Addiction Research 5: 519-548

Galski T, Williams JB, Ehle HT (2000) Effects of opioids on driving ability. Journal of Pain and Symptom Management 19: 200-208

Gawin FH (1991) Cocaine addiction: psychology and neurophysiology. Science 251: 1580-6.

Giacomuzzi SM, Ertl M, Vigl A, Riemer Y, Gunther V, Kopp M, Pilsz W, Haaser W (2005) Driving capacity of patients treated with methadone and slow-release oral morphine. Addiction 100: 1027

Gouzoulis Mayfrank E, Daumann J (2006) Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101: 348-61

Grant BF, Harford TC (1990) Concurrent and simultaneous use of alcohol with cocaine: results of national survey. Drug Alcohol Depend 25: 97-104.

Hall WD (2006) Cannabis use and the mental health of young people. Aust N Z J Psychiatry 40: 105-13

Halpern JH, Pope HG (1999) Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend 53: 247-56

Hanks GW, O'Neill WM, Simpson P, Wesnes K (1995) The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. Eur J Clin Pharmacol 48: 455-60

Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") [see comments]. Lancet 340: 384-7

Hernandez-Lopez C, Farre M, Roset PN, Menoyo E, Pizarro N, Ortuno J, Torrens M, Cami J, de La Torre R (2002) 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300: 236-44

Hetem LAB, Danion JM, Diemunsch P, Brandt C (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152: 283–288

Higgins ST, Bickel WK, Hughes JR, Lynn M, Capeless MA (1990) Effects of intranasal cocaine on human learning, performance and physiology. psychopharmacology 102: 451-458

Higgins ST, Katz JL (1998) Cocaine abuse: Behavior, pharmacology and clinical applications. Academic Press, Academic Press

Higgins ST, Rush CR, Bickel WK, Hughes JR, Lynn M, Capeless MA (1993) Acute behavioral and cardiac effects of cocaine and alcohol combinations in humans. Psychopharmacology 111: 285-94

Hill JL, Zacny JP (2000) Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers. Psychopharmacology (Berl) 152: 31-9

Isaacs SO, Martin P, Washington JA, Jr. (1986) Phencyclidine (PCP) abuse. A close-up look at a growing problem. Oral Surg Oral Med Oral Pathol 61: 126-9

Izenwasser S (1998) Basic Pharmacological mechanisms of cocaine. In: Higgins ST, Katz JL (eds) Cocaine abuse: Behavior, Pharmacology and CLinical Applications. Academic Press, San Diego, pp 1-20

Jaffe JH, Knapp CM, Ciraulo DA (1997) Opiates: clinical aspects. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance Abuse: A Comprehensive Textbook. Williams & Wilkins, Baltimore, pp 158-166

Jaffe JH, Martin WR (1990) Opioid analgesic and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's: The pharmacological basis of therapeutics. Pergamon Press, New York, pp 485-521

Janiszewski DJ, Galinkin JL, Klock PA, Coalson DW, Pardo H, Zacny JP (1999) The effects of subanesthetic concentrations of sevoflurane and nitrous oxide, alone and in combination, on analgesia, mood, and psychomotor performance in healthy volunteers. Anesth Analg 88: 1149-54

Jansen KL (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32: 419-33

Johnson B, Overton D, Wells L, Kenny P, Abramson D, Dhother S, Chen YR, Bordnick P (1998) Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts. Psychiatry Res 77: 35-42.

Johnson B, Overton D, Wells L, Kenny P, Abramson D, Dhother S, Chen YR, Bordnick P (1999) Effects of acute intravenous cocaine on cardiovascular function, human learning, and performance in cocaine addicts. Psychiatry Research 77: 35-42

Joranson DE, Ryan KM, Gilson AM, Dahl JL (2000) Trends in medical use and abuse of opioid analgesics. JAMA 283: 1710-4

King GR, Ellinwood EH (1997) Amphetamines and other stimulants. In: Lowinson JH, Ruiz p, Millman RB, Langrod JG (eds) Substance Abuse; a comprehensive textbook. Williams & Wilkins, Baltimore, pp 207-223

Koelega HS (1993) Stimulant drugs and vigilance performance: A review. Psychopharmacology 111: 1-16

Kress HG, Kraft B (2005) Opioid medication and driving ability. Eur J Pain 9: 141-4

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr., Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214

Kurtzman TL, Otsuka KN, Wahl RA (2001) Inhalant abuse by adolescents. J Adolesc Health 28: 170-80

Kuypers KPC, Ramaekers JG (2006) Acute dose of MDMA (75mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacoloy In press

Kuypers KPC, Samyn N, Ramaekers JG (2006) MDMA-alcohol interaction effects on actual driving and psychomotor function. Submitted

Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-67

Lamers CT, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N, Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 17: 379-87

Lamers CTJ, Ramaekers JG (2001) Visual search and urban city driving under the influence of marijuana and alcohol. Human Psychopharmacology 16: 393-401

Laumon B, Gadegbeku B, Martin JL, Biecheler MB (2005) Cannabis intoxication and fatal road crashes in France: population based case-control study. Bmj 331: 1371

Lenne MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ (2003) The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72: 271-8

Licata A, Taylor S, Berman M, Cranston J (1993) Effects of cocaine on human aggression. Pharmacol Biochem Behav 45: 549-52.

Logan BK (1996) Methamphetamine and driving impairment. J Forensic Sci 41: 457-64

Logan BK, Couper FJ (2001) 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci 46: 1426-33

Louwerens JW, Gloerich ABM, Vries Gd, Brookhuis KA, O'Hanlon JF (1987) The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel.

In: Noordzij PC, Roszbach R (eds) Alcohol, drugs and traffic safety-T86. Elsevier, Amsterdam, pp 183-186

Lund AK, Preusser DF, Blomberg RD, Williams AF (1988) Drug use by tractor-trailer drivers. J Forensic Sci 33: 648-61

Lundqvist T (2005) Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81: 319-30

Maes V, Charlier C, Grenez O, Verstraete A (1999) Drugs and medicines that are suspected to have a detrimental impact on road user performance. The Toxicological Society of Belgium and Luxembourg (BLT) as subcontractor of University of Gent (RUG), Gent

Marzuk PM, Tardiff K, Leon AC, Stajic M, Morgan EB, Mann JJ (1990) Prevalence of recent cocaine use among motor vehicle fatalities in New York City. Jama 263: 250-6.

Mathew RJ, Wilson WH, Tant SR (1989) Regional cerebral blood flow changes associated with amyl nitrite inhalation. Br J Addict 84: 293-99

McCann UD, Ricaurte GA (2004) Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci Biobehav Rev 27: 821-6

McGregor C, Darke S, Ali R, Christie P (1998) Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction 93: 701-11

McKenna DJ (1996) Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res 73: 109-16

Meredith TJ, Ruprah M, Liddle A, Flanagan RJ (1989) Diagnosis and treatment of acute poisoning with volatile substances. Hum Toxicol 8: 277-286

Mintzer MZ, Stitzer ML (2002) Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 67: 41-51

Moeller MR, Hartung M (1997) Ecstasy and related substances-serum levels in impaired drivers. Journal of Analytical Toxicology 21: 591

Montoya AG, Sorrentino R, Lukas SE, Price BH (2002) Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review. Harv Rev Psychiatry 10: 212-20

Moran R (1999) Literature Review on the Relation between Drug Use, Impaired Driving and Traffic Accidents. EMCDDA/HRB, Health Research Board, Drugs Misuse Research Division, Tel. 00 353 1 6761176, email rmoran@hrb.ie, Dublin

Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152: 230-48

Mørland J (2000) Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Toxicol Lett 112-113: 147-52

Musshoff F, Junker H, Madea B (2002) An unusual case of driving under the influence of enflurane. Forensic Science International 128: 187-189

Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118

Newhouse PA, Belenky G, Thomas M, Thorne D, Sing HC, Fertig J (1989) The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacology 2: 153-64

Nnadi CU, Mimiko OA, McCurtis HL, Cadet JL (2005) Neuropsychiatric effects of cocaine use disorders. J Natl Med Assoc 97: 1504-15

O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K (2000) The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 85: 209-15

Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22: 293-302

Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW (2000) Profiles of Cognitive Dysfunction in Chronic Amphetamine and Heroin Abusers. Neuropsychopharmacology 23: 113-126

Peck RC, Biasotti A, Boland PN, malloy C (1986) The effects of marijuana and alochol on actual driving performance. Alcohol, Drugs and Driving 2: 135-154

Pickworth WB, Rohrer MS, Fant RV (1997) Effects of Abused Drugs on Psychomotor Performance. Experimental and Clinical Psychopharmacology 5: 235–241

Pradhan SN (1984) Phencyclidine (PCP): some human studies. Neurosci Biobehav Rev 8: 493-501

Ramaekers JG, Berghaus G, van Laar M, Drummer OH (2004) Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 73: 109-19

Ramaekers JG, Kuypers KP (2006) Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol. Neuropsychopharmacology in press

Ramaekers JG, Kuypers KPC, Samyn N (2006a) Stimulant effects of MDMA 75mg and methylphenidate 20mg on actual driving during intoxicationa and withdrawal. Submitted

Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G (2006b) Cognition and motor control as a function of delta-9-THC concentration in serum and oral fluid: limits of impairment. Submitted

Ramaekers JG, Robbe HWJ, O'Hanlon JF (2000) Marijuana, alcohol and actual driving performance. Hum Psychopharmacol 15: 551-8

Reisine T, Pasternak G (1996) Opioid analgesic and antagonists. In: Gilman Goodman A, Goodman LS, Gilman A, Hardman JG, Molinoff PB, Ruddon RW, Limbird LE (eds) Goodman and Gilman's: The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, pp 521-555

Riba J, Rodriguez Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC, Barbanoj MJ (2001) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154: 85-95

Riedel WJ, Vermeeren A, Van Boxtel MPJ, Vuurman EFPM, Verhey FRJ, Jolles J, Ramaekers JG (1998) Mechanisms of Drug-Induced Driving Impairment: A Dimensional Approach. Human Psychopharmacology 13: S49-63

Robbe HWJ (1994) Influence of marijuana on driving. Datawyse, Datawyse

Robbe HWJ (1998) Marijuana's impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Human Psychopharmacology 13: S70-78

Rosenberg NL, Grigsby J, Dreisbach J, Busenbark D, Grigsby P (2002) Neuropsychologic impairment and MRI abnormalities associated with chronic solvent abuse. J Toxicol Clin Toxicol 40: 21-34

Rothenberg S, Schottenfeld S, Gross K, Selkoe D (1977) Performance differences between addicts and non-addicts. Psychopharmacology 52: 299-306

Rush CR, Baker RW, Wright K (1999) Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis Drug Alcohol Depend 55: 1-12

Schermer CR, Wisner DH (1999) Methamphetamine use in trauma patients: a population-based study. J Am Coll Surg 189: 442-9

Schifano F (1995) Dangerous Driving and MDMA ("Ecstasy") abuse. Journal of Serotonin Research 1: 53-57

Schindler SD, Ortner R, Peternell A, Eder H, Opgenoorth E, Fischer G (2004) Maintenance therapy with synthetic opioids and driving aptitude. Eur Addict Res 10: 80-7

Seppälä T, Linnoila M, Mattila MJ (1979) Drugs, alcohol and driving. Drugs 17: 389-408

Sharp CW, Rosenberg NL (1997) Inhalants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance Abuse; a Comprehensive Textbook. Williams & Wilkins, Baltimore, pp 246-258

Silber BY, Papafotiou K, Croft RJ, Ogden E, Swann P, Stough C (2005) The effects of dexamphetamine on simulated driving performance. Psychopharmacology (Berl) 179: 536-43

Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9: 222-31.

Smiley AM, Moskowitz H, Ziedman K (1981) Driving simulator studies of marijuana alone and in combination with alcohol 25th Conference of the American Association of Automotive Medicine, pp 107-116

Smith AM (1996) Patients taking stable doses of morphine may drive. BMJ 312: 56-7

Soetens E, Casaer S, D'Hooge R, Hueting JE (1995) Effect of amphetamine on long-term retention of verbal material. Psychopharmacology 119: 155-62

Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H (2005) Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 25: 490-3

Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M (2000) Cognitive-motor performance of methadone-maintained patients. Eur Addict Res 6: 8-19

Stein AC, Allen RW, Cook ML, Karl RL (1983) A simulator study of the combined effects of alcohol and marihuana on driving behaviour. National Highway Safety Traffic Administration Systems Technology Inc Hawthorne California

Stillman R, Jones RT, Moore D, Walker J, Welm S (1993) Improved performance 4 hours after cocaine. Psychopharmacology 110: 415-20

Substance Abuse and Mental Health Services Administration (2005) Overview of findings from the 2004 national survey on drugs use and health. Office of Applied Studies, NSDUH Series H-27, DHHS Publication No.SMA 05-4061, Rockville, MD

Uzun N, Kendirli Y (2005) Clinical, socio-demographic, neurophysiological and neuropsychiatric evaluation of children with volatile substance addiction. Child Care Health Dev 31: 425-32

Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346: 667-70

Van Berckel BNM, Oranje B, van Ree JM, Verbaten MN, Kahn RS (1998) The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacology 137: 271-281

Verdejo A, Toribio I, Orozco C, Puente KL, Perez Garcia M (2005) Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 78: 283-8

Verdejo Garcia A, Lopez Torrecillas F, Gimenez CO, Perez Garcia M (2004) Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol Rev 14: 1-41

Vollenweider FX, Gamma A, Liechti M, Huber T (1998a) Psychological and cardiovascular effects and short-term sequelae of MDMA (ectasy) in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19: 241-251

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997a) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25-38

Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997b) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7: 9-24

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998b) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-902

Voth EA, Schwartz RH (1997) Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 126: 791-8

Walker DJ, Zacny JP (1998) Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology (Berl) 140: 191-201

Walker DJ, Zacny JP (1999) Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289: 1454-64

Walker DJ, Zacny JP (2001) Within- and between-subject variability in the reinforcing and subjective effects of nitrous oxide in healthy volunteers. Drug Alcohol Depend 64: 85-96

Walker DJ, Zacny JP (2003) Bitonic dose-response functions for reinforcing and self-reported effects of nitrous oxide in humans. Pharmacol Biochem Behav 74: 851-7

White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49: 455-79

Woody GE (1970) Visual disturbances experienced by hallucinogenic drug abusers while driving. American Journal of Psychiatry 127: 683-686

Zacny JP (1995) A review of the effects of opioids on psychomotor and cognitive functioning in humans. Experimental and Clinical Psychopharmacology 3: 432-466

Zacny JP (1996a) Should people taking opioids for medical reasons be allowed to work and drive? Addiction 91: 1581-4

Zacny JP (1996b) Should people taking opioids for medical reasons be allowed to work and drive? [editorial]. Addiction 91: 1581-4

Zacny JP, Coalson DW, Lichtor JL, Yajnik S, Thapar P (1994a) Effects of naloxone on the subjective and psychomotor effects of nitrous oxide in humans. Pharmacol Biochem Behav 49: 573-8

Zacny JP, Hill JL, Black ML, Sadeghi P (1998) Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J Pharmacol Exp Ther 286: 1197-207

Zacny JP, Janiszewski D, Sadeghi P, Black ML (1999) Reinforcing, subjective, and psychomotor effects of sevoflurane and nitrous oxide in moderate-drinking healthy volunteers. Addiction 94: 1817-28

Zacny JP, Lichtor JL, Coalson DW, Apfelbaum JL, Flemming D, Foster V (1994b) Time course of effects of brief inhalations of nitrous oxide in normal volunteers. Addiction 89: 831-9

Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK (1994c) A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 268: 1-9

View publication stats